High Dose Epoetin Beta in the First Weeks Following Renal Transplantation and Delayed Graft Function: Results of the Neo‐PDGF Study

Erythropoietin promotes nephroprotection in animal models of ischemia‐reperfusion injury. Neorecormon® and Prevention of Delayed Graft Function (Neo‐PDGF) is a French open‐label multicenter randomized study to evaluate the effect of high doses of epoetin beta (EPO‐β) during the first 2 weeks of rena...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of transplantation Vol. 10; no. 7; pp. 1695 - 1700
Main Authors:	Martinez, F., Kamar, N., Pallet, N., Lang, P., Durrbach, A., Lebranchu, Y., Adem, A., Barbier, S., Cassuto‐Viguier, E., Glowaki, F., Le Meur, Y., Rostaing, L., Legendre, C., Hermine, O., Choukroun, G.
Format:	Journal Article
Language:	English
Published:	Malden, USA Blackwell Publishing Inc 01-07-2010 Wiley Elsevier
Subjects:	Adrenal Cortex Hormones - therapeutic use Aged Antibodies, Monoclonal - therapeutic use Basiliximab Biological and medical sciences Blood Pressure Body Mass Index Cardiology. Vascular system Creatinine - blood Delayed graft function Delayed Graft Function - drug therapy epoetin Erythropoietin - therapeutic use Female France Glomerular Filtration Rate - drug effects Graft Rejection - epidemiology Hemoglobins - metabolism Humans Immunosuppressive Agents - therapeutic use ischemia‐reperfusion Kidney Transplantation - adverse effects Kidney Transplantation - immunology Kidney Transplantation - physiology Male Medical sciences Middle Aged Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use Platelet-Derived Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Recombinant Proteins Renal Dialysis renal transplantation Safety Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Tacrolimus - therapeutic use Kidney disease Urinary system disease Renal function Ischemia reperfusion renal transplantation ischemia-reperfusion Homotransplantation Antianemia agent Kidney Delayed graft function Result Treatment Urinary system Surgery epoetin Graft Epoetin beta High dose Platelet derived growth factor Growth factor Kidney transplantation
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Erythropoietin promotes nephroprotection in animal models of ischemia‐reperfusion injury. Neorecormon® and Prevention of Delayed Graft Function (Neo‐PDGF) is a French open‐label multicenter randomized study to evaluate the effect of high doses of epoetin beta (EPO‐β) during the first 2 weeks of renal transplantation on renal function in patients at risk for delayed graft function (DGF). One hundred and four patients were included in the study. Patients randomized in treatment group (A) received four injections of EPO‐β (30.000 UI each), given before surgery and at 12 h, 7 days and 14 days posttransplantation. Patients randomized in control group (B) did not receive EPO‐β. Immunosuppression included induction with basiliximab and maintenance therapy with steroids, mycophenolate mofetil and tacrolimus. At 1 month posttransplant, the estimated glomerular filtration rate (MDRD formula) was 42.5 ± 19.0 mL/min in the EPO‐β group and 44.0 ± 16.3 mL/min in the control group (p = ns). The frequency of DGF was similar in both groups (32% vs. 38.8%; p = ns). No difference in the incidence of serious adverse events was observed. (ClinicalTrials.gov number, NCT00815867.) High‐dose epoietin‐β has no beneficial effect with regard to renal function at one and three months after renal transplantation in patients at risk for delayed graft function.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	1600-6135 1600-6143
DOI:	10.1111/j.1600-6143.2010.03142.x